Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.
PMID: 29040633
2017
The Journal of infectious diseases
Abstract: PDR was defined as >=2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing.
Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.
Abstract: The most frequent NRTIs drug resistance associated mutations are mainly the lamivudine-induced mutation M184V which was detected in 4 patients at T1 and showed a 2 fold increase in the following time points (T2: n = 8) and at (T3: n = 12) and the thymidine analogue mutations (such as D67N, K70R and K219E) which were not-detected at baseline T0 and T1 but were increased progressively to 10 at T2 and to 17 at T3.
Result: But eventually observed in 5/8, 8/11 and 12/15 patients at time point T1 (S2 Table), T2 (Table 1) and T3 (Table 2), respectively with frequent combination of M184V and NNRTI resistance associated mutations.
Result: The most frequent
Table: M184V
Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.
PMID: 29068286
2017
Journal of medical microbiology
Abstract: The most frequent mutations were lamivudine-resistance M184V and efavirenz/nevirapine-resistance K103N.
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Abstract: Overall, 7.3% transmitted and 34.3% acquired DRMs were found, including M184V, thymidine analogue mutations (T215F, D67N, K70R, K219Q), NNRTIs (L100I, Y181C, K103N, V108I, Y188L), and PIs (V82L).
Discussion: In addition to the resistance mutations to NRTIs (M184V and the TAM T215F) and NNRTIs (L100I, Y181C,
HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
PMID: 29091218
2017
The Journal of antimicrobial chemotherapy
Abstract: At the time of DOLULAM initiation, M184V was observed in DNA NGS in five patients, including one as MRV.
Abstract: Combining all available genotype data, an M184I/V was observed in 17 of 27 (63%) of the patients.
Abstract: Conclusions: These first NGS data on HIV DNA at initiation of a switch study showed (i) a high proportion of patients harbouring defective viral genomes, whose mutation M184I is a marker, and (ii) a low number of patients in whom M184V remained as a major viral variant in PBMCs.
Abstract: Most M184V were detected in historical RNA genotypes (n = 8 of 11), whereas M184I were exclusively detected in DNA genotypes (n = 10, including 7 as MRV).
Abstract: Objectives: A virological substudy was conducted to assess the prevalence
Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals.
Result: A direct robust interaction was observed between treatment experience (eRT) and known NRTI-elicited mutations M184I/V and K70E/R.
Result: The most frequently observed reverse transcriptase (RT) drug resistance mutations in NRTI-experienced patients were M184I/V (64.2%), D67N (25.9%), K70R (19.6%), K219Q/E (17.9%) and T215Y/F (13.4%).
Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Result: Out of the 43 sequences generated, the most prevalent DRMs were: (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V, followed by other DRMs observed at low rates.
Discussion: Complementary studies are needed to ascertain response after switch from first- to second-line, to evaluate the feasibility of point-of-care resistance testing designed with commonly found mutations (M184V/I, T215mutants, K103N, Y181C) for greater cost-effectiveness, and monitoring HIVDR early warning indicators.
Discussion: Even though 3TC and FTC are highly
[Drug resistance mutations and its associated factors among 579 HIV/AIDS patients experiencing failure of antiretroviral therapy in Jiangsu Province, China].
PMID: 29136743
2017
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: M184V/I and K103N/Q were the highest frequency of NRTI and NNRTI resistance mutation, the prevalence of M184V/I and K103N/Q were 28.15% and 22.28%, respectively.
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
Abstract: Among 1103 subjects using a nucleos(t)ide reverse transcriptase inhibitor (N[t]RTI) backbone, 10 (0.9%) developed >= 1 N(t)RTI RAM (8 had the emtricitabine RAM M184I/V).
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.
Abstract: The M184V mutation was found in both FSWs on treatment (12/14, 85.7%) and those defaulting (1/5, 20.0%).
Result: Overall, the number of FSWs with the K103N mutation was 68.9% (31/45), the K101E mutation was found in 6/45 (13.3%), the V106M mutation in 10/45 (22.2%), G190A in 5/45 (11.1%), and the NRTI mutation M184V was present in 13/45 (28.9%) of SWs.
Result: The NRTI mutation M184V was also found in 1 participant.
HIV mutation literature information.
PMID: 
2017
The Journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT